Parkinson’s Disease / 2017 / Article / Tab 2

Clinical Study

A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinson’s Disease

Table 2

Efficacy result of JLT on Parkinson’s disease patient at week 32.

JLTPlaceboMean difference95% confidence interval (CI)p value

Movement Disorder Society-Sponsored Revision of Unified PD Rating Scale
(MDS-UPDRS)
Part I total score (nonmotor symptom)−0.46 ± 6.610.84 ± 4.09−1.30−3.37 to 0.770.215
 Q.1 Cognitive−0.07 ± 0.970.00 ± 0.69−0.07−0.39 to 0.250.657
 Q.2 Hallucinations−0.04 ± 0.540.15 ± 0.52−0.18−0.38 to 0.020.075
 Q.3 Depression−0.07 ± 1.030.07 ± 0.72−0.14−0.48 to 0.190.393
 Q.4 Anxious−0.14 ± 0.82−0.02 ± 0.71−0.13−0.41 to 0.160.393
 Q.5 Apathy−0.23 ± 1.36−0.02 ± 0.87−0.21−0.64 to 0.220.327
 Q.6 Dopamine dysregulation−0.13 ± 0.63−0.15 ± 0.520.02−0.20 to 0.240.854
 Q.7 Sleep0.23 ± 1.030.13 ± 1.060.11−0.29 to 0.500.597
 Q.8 Daytime sleep0.16 ± 0.910.11 ± 0.850.05−0.28 to 0.380.759
 Q.9 Pain−0.02 ± 1.300.24 ± 1.05−0.25−0.70 to 0.190.261
 Q.10 Urinary−0.02 ± 0.730.02 ± 0.87−0.04−0.34 to 0.270.813
 Q.11 Constipation−0.13 ± 1.450.96 ± 4.35−1.19−2.30 to 0.130.079
 Q12 Light headedness0.04 ± 1.08−0.04 ± 0.380.72−0.23 to 0.380.641
 Q13 Fatigue−0.04 ± 1.21−0.02 ± 0.97−0.05−0.47 to 0.360.796
Part II total score (motor symptom)0.45 ± 4.131.05 ± 4.58−0.61−2.25 to 1.030.464
Part III total score (motor examination)−0.52 ± 10.131.38 ± 8.27−1.90−5.38 to 1.580.282
Part IV total score (motor complications)0.21 ± 3.560.65 ± 3.42−0.44−1.75 to 0.870.508

Nonmotor Symptom Assessment Scale for Parkinson’s Disease
(NMSS)
Total score−2.27 ± 32.9011.78 ± 28.93−14.05−25.71 to −2.390.019
 D1 total cardiovascular−0.89 ± 3.38−0.15 ± 2.31−0.75−1.84 to 0.350.178
 D2 total sleep/fatigue3.63 ± 7.984.62 ± 7.08−0.99−3.83 to 1.840.490
 D3 total mood/cognition−3.54 ± 14.383.13 ± 9.36−6.66−11.23 to −2.100.005
 D4 total perceptual/hallucinations−0.88 ± 4.170.71 ± 3.04−1.58−2.96 to −0.210.024
 D5 total attention/memory−1.86 ± 6.07−0.15 ± 7.08−1.71−4.20 to 0.770.174
 D6 total gastrointestinal tract−0.86 ± 5.150.98 ± 5.66−1.84−3.87 to 0.200.076
 D7 total urinary1.71 ± 7.571.47 ± 7.120.24−2.52 to 3.010.863
 D8 total sexual function−0.71 ± 4.200.16 ± 3.81−0.88−2.39 to 0.630.251
 D9 total miscellaneous1.13 ± 6.411.00 ± 5.460.13−2.11 to 2.360.912

p value wascomparing the score changes at week 32 between JLT group and placebo group by independent sample t-tests; values are given as mean ± S.D. Values in JLT group and placebo group are the score changed in the same group between week 32 and baseline (score at week 32 minus score at the baseline).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.